Curasight A/S (NGM:CURAS)
Sweden · Delayed Price · Currency is SEK · Price in DKK 8.86
+0.48 (5.73%)
At close: Sep 30, 2026
Curasight Earnings Call Transcripts
Fiscal Year 2024
-
H1 2024 saw increased losses due to higher development activity, but key milestones were achieved, including EMA approval and first patient enrollment in a phase II prostate cancer trial, triggering a milestone payment. A new funding structure could secure up to DKK 120 million, supporting clinical progress and strategic flexibility.